TMEM102

Across TCGA pan-cancer cohorts, TMEM102 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMEM102 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMEM102 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TMEM102 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where TMEM102 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.916	0.738	.007	38	view →
CCRCC	OS	Median	II,III,IV	1.000	0.373	.006	26	view →
LUAD	DFS	Tertile	All	0.361	0.728	.002	23	view →
LSCC	DFS	Median	All	0.990	0.886	.007	10	view →
UCEC	DFS	Median	All	0.934	0.781	.018	10	view →
GBM	OS	Median	All	0.245	0.457	.004	6	view →
HNSC	OS	Median	IV	0.928	0.759	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMEM102–PDAC (OS)

Open the PDAC breakdown →